1
|
Villoslada P, Solana E, Alba-Arbalat S, Martinez-Heras E, Vivo F, Lopez-Soley E, Calvi A, Camos-Carreras A, Dotti-Boada M, Bailac RA, Martinez-Lapiscina EH, Blanco Y, Llufriu S, Sanchez Dalmau BF. Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis. NEUROLOGY(R) NEUROIMMUNOLOGY & NEUROINFLAMMATION 2024; 11:e200288. [PMID: 39213469 PMCID: PMC11368233 DOI: 10.1212/nxi.0000000000200288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 06/07/2024] [Indexed: 09/04/2024]
Abstract
BACKGROUND AND OBJECTIVES Recovery of vision after acute optic neuritis (AON) is critical to improving the quality of life of people with demyelinating diseases. The objective of the study was to prospectively assess the changes in visual acuity, retinal layer thickness, and cortical visual network in patients with AON to identify the predictors of permanent visual disability. METHODS We studied a prospective cohort of 88 consecutive patients with AON with 6-month follow-up using high and low-contrast (2.5%) visual acuity, color vision, retinal thickness from optical coherence tomography, latencies and amplitudes of multifocal visual evoked potentials, mean deviation of visual fields, and diffusion-based structural (n = 53) and functional (n = 19) brain MRI to analyze the cortical visual network. The primary outcome was 2.5% low-contrast vision, and data were analyzed with mixed-effects and multivariate regression models. RESULTS We found that after 6 months, low-contrast vision and quality of vision remained moderately impaired. The thickness of the ganglion cell layer at baseline was a predictor of low-contrast vision 6 months later (ß = 0.49 [CI 0.11-0.88], p = 0.012). The structural cortical visual network at baseline predicted low-contrast vision, the best predictors being the betweenness of the right parahippocampal cortex (ß = -036 [CI -0.66 to 0.06], p = 0.021), the node strength of the right V3 (ß = 1.72 [CI 0.29-3.15], p = 0.02), and the clustering coefficient of the left intraparietal sulcus (ß = 57.8 [CI 12.3-103.4], p = 0.015). The functional cortical visual network at baseline also predicted low-contrast vision, the best predictors being the betweenness of the left ventral occipital cortex (ß = 8.6 [CI: 4.03-13.3], p = 0.009), the node strength of the right intraparietal sulcus (ß = -2.79 [CI: -5.1-0.4], p = 0.03), and the clustering coefficient of the left superior parietal lobule (ß = 501.5 [CI 50.8-952.2], p = 0.03). DISCUSSION The assessment of the visual pathway at baseline predicts permanent vision disability after AON, indicating that damage is produced early after disease onset and that it can be used for defining vision impairment and guiding therapy.
Collapse
Affiliation(s)
- Pablo Villoslada
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Elisabeth Solana
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Salut Alba-Arbalat
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Eloy Martinez-Heras
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Francesc Vivo
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Elisabet Lopez-Soley
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Alberto Calvi
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Anna Camos-Carreras
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Marina Dotti-Boada
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Rafel Alcubierre Bailac
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Elena H Martinez-Lapiscina
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Yolanda Blanco
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Sara Llufriu
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| | - Bernardo F Sanchez Dalmau
- From the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain
| |
Collapse
|
2
|
Klyscz P, Asseyer S, Alonso R, Bereuter C, Bialer O, Bick A, Carta S, Chen JJ, Cohen L, Cohen‐Tayar Y, Carnero Contentti E, Dale RC, Flanagan EP, Gernert JA, Haas J, Havla J, Heesen C, Hellmann M, Levin N, Lopez P, Lotan I, Luis MB, Mariotto S, Mayer C, Vergara AJM, Ocampo C, Ochoa S, Oertel FC, Olszewska M, Uribe JLP, Sastre‐Garriga J, Scocco D, Ramanathan S, Rattanathamsakul N, Shi F, Shifa J, Simantov I, Siritho S, Tiosano A, Tisavipat N, Torres I, Dembinsky AV, Vidal‐Jordana A, Wilf‐Yarkoni A, Wu T, Zamir S, Zarco LA, Zimmermann HG, Petzold A, Paul F, Stiebel‐Kalish H. Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network. Ann Clin Transl Neurol 2024; 11:2473-2484. [PMID: 39099240 PMCID: PMC11537134 DOI: 10.1002/acn3.52166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 07/03/2024] [Accepted: 07/16/2024] [Indexed: 08/06/2024] Open
Abstract
OBJECTIVE The first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON). METHODS We included 160 patients with a first-ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present. RESULTS According to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody-associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%). INTERPRETATION According to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.
Collapse
Affiliation(s)
- Philipp Klyscz
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Department of Neurology, Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Susanna Asseyer
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Department of Neurology, Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Ricardo Alonso
- University Center of MS and NMOSD, Neurology DepartmentRamos Mejia HospitalBuenos AiresArgentina
| | - Charlotte Bereuter
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Omer Bialer
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
| | - Atira Bick
- Department of Neurology, Hadassah Medical CenterHebrew UniversityJerusalemIsrael
| | - Sara Carta
- Neurology Unit, Department of Neurosciences, Biomedicine, and Movement SciencesUniversity of VeronaVeronaItaly
| | - John J. Chen
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
- Center for MS and Autoimmune NeurologyMayo ClinicRochesterMinnesotaUSA
- Department of OphthalmologyMayo ClinicRochesterMinnesotaUSA
| | - Leila Cohen
- University Center of MS and NMOSD, Neurology DepartmentRamos Mejia HospitalBuenos AiresArgentina
| | - Yamit Cohen‐Tayar
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
- Eye Laboratory, Felsenstein Medical Research CenterTel Aviv UniversityTel AvivIsrael
| | | | - Russell C. Dale
- TY Nelson Department of Paediatric NeurologyChildren's Hospital at WestmeadSydneyNew South WalesAustralia
- Faculty of Medicine and Health and Brain and Mind CentreUniversity of SydneySydneyNew South WalesAustralia
- Clinical Neuroimmunology Group, Kids Neuroscience CentreChildren's Hospital at WestmeadSydneyNew South WalesAustralia
| | - Eoin P. Flanagan
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
- Center for MS and Autoimmune NeurologyMayo ClinicRochesterMinnesotaUSA
- Department of Laboratory Medicine and PathologyMayo ClinicRochesterMinnesotaUSA
| | - Jonathan A. Gernert
- Institute of Clinical Neuroimmunology, LMU HospitalLudwig‐Maximilians‐Universität MunichMunichGermany
| | - Julian Haas
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Joachim Havla
- Institute of Clinical Neuroimmunology, LMU HospitalLudwig‐Maximilians‐Universität MunichMunichGermany
| | - Christoph Heesen
- Institute of Neuroimmunology and Multiple SclerosisUniversity Medical Center Hamburg EppendorfHamburgGermany
| | - Mark Hellmann
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
| | - Netta Levin
- Department of Neurology, Hadassah Medical CenterHebrew UniversityJerusalemIsrael
| | - Pablo Lopez
- Neuroimmunology Unit, Department of NeuroscienceHospital AlemanBuenos AiresArgentina
| | - Itay Lotan
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
- Neuroimmunology Service, Department of NeurologyRabin Medical CenterPetah TikvaIsrael
- Neuromyelitis Optica Research Laboratory, Massachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Maria Belen Luis
- University Center of MS and NMOSD, Neurology DepartmentRamos Mejia HospitalBuenos AiresArgentina
| | - Sara Mariotto
- Neurology Unit, Department of Neurosciences, Biomedicine, and Movement SciencesUniversity of VeronaVeronaItaly
| | - Christina Mayer
- Institute of Neuroimmunology and Multiple SclerosisUniversity Medical Center Hamburg EppendorfHamburgGermany
| | | | | | - Susana Ochoa
- University Center of MS and NMOSD, Neurology DepartmentRamos Mejia HospitalBuenos AiresArgentina
| | - Frederike C. Oertel
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Department of Neurology, Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Maja Olszewska
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | | | - Jaume Sastre‐Garriga
- Neurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat)Vall d’Hebron University HospitalBarcelonaSpain
| | - Dario Scocco
- University Center of MS and NMOSD, Neurology DepartmentRamos Mejia HospitalBuenos AiresArgentina
| | - Sudarshini Ramanathan
- Faculty of Medicine and Health and Brain and Mind CentreUniversity of SydneySydneyNew South WalesAustralia
- Department of NeurologyConcord HospitalSydneyNew South WalesAustralia
- Translational Neuroimmunology Group, Kids Neuroscience CentreChildren's Hospital at WestmeadSydneyNew South WalesAustralia
| | | | - Fu‐Dong Shi
- Department of NeurologyTianjin Medical University General HospitalTianjinChina
| | - Jemal Shifa
- Department of SurgeryUniversity of BotswanaGaboroneBotswana
| | - Ilya Simantov
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
- Eye Laboratory, Felsenstein Medical Research CenterTel Aviv UniversityTel AvivIsrael
| | - Sasitorn Siritho
- Faculty of Medicine Siriraj HospitalMahidol University BangkokBangkokThailand
- Neuroscience CenterBumrungrad International HospitalBangkokThailand
| | - Alon Tiosano
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
| | - Nanthaya Tisavipat
- Department of NeurologyMayo ClinicRochesterMinnesotaUSA
- Center for MS and Autoimmune NeurologyMayo ClinicRochesterMinnesotaUSA
| | - Isabel Torres
- Pontificia Universidad Javeriana and Hospital Universitario San IgnacioBogotáColombia
| | - Adi Vaknin Dembinsky
- Department of Neurology, Hadassah Medical CenterHebrew UniversityJerusalemIsrael
| | - Angela Vidal‐Jordana
- Neurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat)Vall d’Hebron University HospitalBarcelonaSpain
| | - Adi Wilf‐Yarkoni
- Neuroimmunology Service, Department of NeurologyRabin Medical CenterPetah TikvaIsrael
- Department of Neurology, Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
| | - Ti Wu
- Department of NeurologyTianjin Medical University General HospitalTianjinChina
| | - Sol Zamir
- Department of Neurology, Hadassah Medical CenterHebrew UniversityJerusalemIsrael
| | - Luis Alfonso Zarco
- Pontificia Universidad Javeriana and Hospital Universitario San IgnacioBogotáColombia
| | - Hanna G. Zimmermann
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Einstein Center Digital FutureBerlinGermany
| | - Axel Petzold
- The National Hospital for Neurology and NeurosurgeryUniversity College LondonLondonUK
- Moorfields Eye HospitalLondonUK
- Neuro‐ophthalmology Expert CentreAmsterdamNetherlands
| | - Friedemann Paul
- Experimental and Clinical Research CenterA Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité ‐ Universitätsmedizin BerlinBerlinGermany
- Department of Neurology, Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)BerlinGermany
- Neuroscience Clinical Research Center (NCRC), Charité ‐ Universitätsmedizin BerlinCorporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
| | - Hadas Stiebel‐Kalish
- Department of Neuro‐OphthalmologyRabin Medical CenterPetah TikvaIsrael
- Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
- Eye Laboratory, Felsenstein Medical Research CenterTel Aviv UniversityTel AvivIsrael
| |
Collapse
|
3
|
Bianchi A, Cortese R, Prados F, Tur C, Kanber B, Yiannakas MC, Samson R, De Angelis F, Magnollay L, Jacob A, Brownlee W, Trip A, Nicholas R, Hacohen Y, Barkhof F, Ciccarelli O, Toosy AT. Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease. Mult Scler 2024; 30:674-686. [PMID: 38646958 PMCID: PMC11103893 DOI: 10.1177/13524585241240420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/27/2024] [Accepted: 03/01/2024] [Indexed: 04/25/2024]
Abstract
BACKGROUND Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, the involvement of the optic chiasm (OC) in IDD has not been fully investigated. AIMS To examine OC differences in non-acute IDD patients with (ON+) and without ON (ON-) using magnetisation transfer ratio (MTR), to compare differences between MS, AQP4 + NMOSD and MOGAD and understand their associations with other neuro-ophthalmological markers. METHODS Twenty-eight relapsing-remitting multiple sclerosis (RRMS), 24 AQP4 + NMOSD, 28 MOGAD patients and 32 healthy controls (HCs) underwent clinical evaluation, MRI and optical coherence tomography (OCT) scan. Multivariable linear regression models were applied. RESULTS ON + IDD patients showed lower OC MTR than HCs (28.87 ± 4.58 vs 31.65 ± 4.93; p = 0.004). When compared with HCs, lower OC MTR was found in ON + AQP4 + NMOSD (28.55 ± 4.18 vs 31.65 ± 4.93; p = 0.020) and MOGAD (28.73 ± 4.99 vs 31.65 ± 4.93; p = 0.007) and in ON- AQP4 + NMOSD (28.37 ± 7.27 vs 31.65 ± 4.93; p = 0.035). ON+ RRMS had lower MTR than ON- RRMS (28.87 ± 4.58 vs 30.99 ± 4.76; p = 0.038). Lower OC MTR was associated with higher number of ON (regression coefficient (RC) = -1.15, 95% confidence interval (CI) = -1.819 to -0.490, p = 0.001), worse visual acuity (RC = -0.026, 95% CI = -0.041 to -0.011, p = 0.001) and lower peripapillary retinal nerve fibre layer (pRNFL) thickness (RC = 1.129, 95% CI = 0.199 to 2.059, p = 0.018) when considering the whole IDD group. CONCLUSION OC microstructural damage indicates prior ON in IDD and is linked to reduced vision and thinner pRNFL.
Collapse
Affiliation(s)
- Alessia Bianchi
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - Rosa Cortese
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
| | - Ferran Prados
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, University College London, London, UK
- eHealth Centre, Universitat Oberta de Catalunya, Barcelona, Spain
| | - Carmen Tur
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- MS Centre of Catalonia (Cemcat), Vall d’Hebron Institute of Research, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Baris Kanber
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, University College London, London, UK
| | - Marios C Yiannakas
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| | - Rebecca Samson
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| | - Floriana De Angelis
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| | - Lise Magnollay
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| | - Anu Jacob
- Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Department of Neurology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Wallace Brownlee
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Biomedical Research Centre, National Institute for Health Research (NIHR), University College London Hospitals (UCLH), London, UK
| | - Anand Trip
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Biomedical Research Centre, National Institute for Health Research (NIHR), University College London Hospitals (UCLH), London, UK
| | - Richard Nicholas
- Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK
| | - Yael Hacohen
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Department of Neurology, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK
| | - Frederik Barkhof
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Centre for Medical Image Computing, Medical Physics and Biomedical Engineering, University College London, London, UK
- Biomedical Research Centre, National Institute for Health Research (NIHR), University College London Hospitals (UCLH), London, UK
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Olga Ciccarelli
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
- Biomedical Research Centre, National Institute for Health Research (NIHR), University College London Hospitals (UCLH), London, UK
| | - Ahmed T Toosy
- Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
| |
Collapse
|
4
|
Cooper AC, Tchernykh M, Shmuel A, Mendola JD. Diffusion tensor imaging of optic neuropathies: a narrative review. Quant Imaging Med Surg 2024; 14:1086-1107. [PMID: 38223128 PMCID: PMC10784057 DOI: 10.21037/qims-23-779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Accepted: 11/21/2023] [Indexed: 01/16/2024]
Abstract
Background and Objective Diffusion tensor imaging (DTI) has been implemented in a breadth of scientific investigations of optic neuropathies, though it has yet to be fully adopted for diagnosis or prognosis. This is potentially due to a lack of standardization and weak replication of results. The aim of this investigation was to review DTI results from studies specific to three distinct optic neuropathies in order to probe its current clinical utility. Methods We reviewed the DTI literature specific to primary open-angle glaucoma (POAG), optic neuritis (ON), and traumatic optic neuropathy (TON) by systematically searching the PubMed database on March 1st, 2023. Four distinct DTI metrics are considered: fractional anisotropy (FA), along with mean diffusivity (MD, axial diffusivity (AD), and radial diffusivity (RD). Results from within-group, between-group, and correlational studies were thoroughly assessed. Key Content and Findings POAG studies most consistently report a decrease in FA, especially in the optic radiations, followed in prevalence by an increase in RD and then MD, whilst AD yields conflicting results between studies. It is notable that there is not an equal distribution of investigated DTI metrics, with FA utilized the most, followed by MD, RD, and AD. Studies of ON are similar in that the most consistent findings are specific to FA, RD, and MD. These results are specific to the optic nerve and radiation since only one study measured the intermediary regions. More studies are needed to assess the effect that ON has on the tracts of the visual system. Finally, only three studies assessing DTI of TON have been performed to date, displaying low to moderate replicability of results. To improve the level of agreement between studies assessing each optic neuropathy, an increased level of standardization is recommended. Conclusions Both POAG and ON studies have yielded some prevalent DTI findings, both for contrast and correlation-based assessments. Although the clinical need is high for TON, considering the limitations of the current diagnostic tools, too few studies exist to make confident conclusions. Future use of standardized and longitudinal DTI, along with the foreseen methodological and technical improvements, is warranted to effectively study optic neuropathies.
Collapse
Affiliation(s)
- Austin C. Cooper
- McGill Vision Research and Department of Ophthalmology, McGill University, Montréal, QC, Canada
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
| | - Maxim Tchernykh
- McGill Vision Research and Department of Ophthalmology, McGill University, Montréal, QC, Canada
| | - Amir Shmuel
- Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
- Departments of Physiology and Biomedical Engineering, McGill University, Montreal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| | - Janine D. Mendola
- McGill Vision Research and Department of Ophthalmology, McGill University, Montréal, QC, Canada
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, QC, Canada
| |
Collapse
|